老年房颤患者华法林与直接口服抗凝药使用趋势
该研究基于2008-2014年医疗保险理赔数据库,分析65岁及以上房颤或房扑患者口服抗凝药使用及转换趋势。结果显示总体抗凝使用率稳定在66%,华法林使用率从69.8%降至42.2%,达比加群和利伐沙班使用率上升,年均约6%的抗凝患者发生药物转换。
要点
- 老年房颤患者总体抗凝使用率保持稳定,约66%接受口服抗凝药。
- 华法林使用率显著下降,从2008年69.8%降至2014年42.2%。
- 直接口服抗凝药使用增加,达比加群和利伐沙班使用率上升。
核心结论
- 研究期间老年房颤或房扑患者总体口服抗凝药使用率保持稳定。
- 2010年起华法林使用逐渐减少,直接口服抗凝药使用相应增加。
研究设计与样本
- 采用医疗和处方理赔数据库进行横断面纵向分析。
- 研究对象为2008-2014年65岁及以上的房颤或房扑医疗保险受益人。
主要发现
- 研究期间66%的房颤或房扑患者接受口服抗凝药。
- 华法林使用率从2008年69.8%下降至2014年42.2%。
- 达比加群使用率从2010年1.3%升至2011年12.1%,后降至2014年7.6%。
- 利伐沙班使用率从2011年0.13%升至2014年13.87%。
- 抗凝患者中平均每年6%发生口服抗凝药转换。
临床怎么用
- 临床应关注老年房颤患者抗凝治疗中直接口服抗凝药使用增加的趋势。
- 需注意抗凝药物转换的普遍性,年均约6%患者发生转换。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Results of a study to determine trends in oral anticoagulant (OAC) use and OAC switching in patients with atrial fibrillation (AF) or atrial flutter are presented. METHODS: Warfarin has been the most prescribed anticoagulant in patients with AF for decades. Since 2010, several direct OACs (DOACs) have gained U.S. marketing approval for stroke prevention in AF or atrial flutter. A cross-sectional longitudinal analysis was conducted using healthcare and prescription claims databases to characterize OAC use and rates of OAC and DOAC switching during the period 2008-14 in cohorts of Medicare beneficiaries 65 years of age or older with AF or atrial flutter. RESULTS: Overall, 66% of patients with AF or atrial flutter were receiving OACs during the study period. The prevalence of warfarin use decreased from 69.8% in 2008 to 42.2% in 2014. This decrease in warfarin use was paralleled by an increase in dabigatran use, which rose from 1.3% in 2010 to 12.1% in 2011 and then declined to 7.6% in 2014. The prevalence of rivaroxaban use increased from 0.13% in 2011 to 13.87% in 2014. Among anticoagulated patients, an average of 6% annually were switched from one OAC to another. CONCLUSION: Overall OAC utilization in patients with AF or atrial flutter remained steady over the study period. Beginning in 2010, a gradual decrease in use of warfarin was paralleled by an increase in use of DOACs.
引用
- Alalwan AA, Voils SA, Hartzema AG, et al. Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation. Am J Health Syst Pharm. 2017. PMID: 28652320. doi:10.2146/ajhp160756
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。